Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 7/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1659344 | 0.91 | HSD11B1 (0.51) | HSD11B1STSHRH3ABCC4ESR1 | |
| SCHEMBL5273029 | 0.89 | HSD11B1 (0.55) | HSD11B1STSHRH3ABCC4ESR1 | |
| SCHEMBL13216959 | 0.79 | STS (0.51) | HSD11B1STSHRH3ESR1SMN1; SMN2 | |
| SCHEMBL1657796 | 0.79 | HSD11B1 (0.49) | HSD11B1STSHRH3ABCC4ESR1 | |
| SCHEMBL13216951 | 0.79 | HSD11B1 (0.52) | HSD11B1STSHRH3ABCC4ESR1 | |
| SCHEMBL8081744 | 0.79 | HSD11B1 (0.52) | HSD11B1STSHRH3ABCC4ESR1 | |
| SCHEMBL5270945 | 0.79 | STS (0.38) | HSD11B1STSHRH3ESR1LMNA | |
| SCHEMBL8089481 | 0.78 | HSD11B1 (0.52) | HSD11B1STSHRH3ABCC4ESR1 | |
| SCHEMBL1659341 | 0.76 | HSD11B1 (0.50) | HSD11B1STSHRH3ABCC4ESR1 | |
| SCHEMBL12968193 | 0.76 | HSD11B1 (0.50) | HSD11B1STSHRH3ABCC4ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305694-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | SRI International (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1847548-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2007-10-24 | — | — | EP | disclosed |
| US-6747018-B2 | TREATMENT OF ESTROGEN-DEPENDENT DISORDERS; PREFERRED COMPOUNDS HAVE 1,3,5-ESTRATRIENE NUCLEUS, AND ARE SUBSTITUTED AT C-17 OR C-11 WITH MOLECULAR MOIETY WHICH RENDERS COMPOUNDS EFFECTIVE TO BLOCK BINDING OF ESTROGEN TO ITS RECEPTOR | SRI INTERNATIONAL | 2004-06-08 | — | — | US | disclosed |
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2003-08-14 | — | — | US | disclosed |
| EP-1310509-A2 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | Sri International (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6548491-B2 | For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated | SRI INTERNATIONAL | 2003-04-15 | — | — | US | disclosed |
| US-6503896-B1 | 17-Desoxy-1,3,5-estratriene derivatives; postmenopause, osteoporosis, central nervous system disorders; anticarcinogenic and hypotensive agents | SRI INTERNATIONAL | 2003-01-07 | — | — | US | disclosed |
| US-6455517-B1 | FOR THERAPY OF CONDITIONS OR DISEASES THAT ARE ESTROGEN-DEPENDENT, I.E., ARE ESTROGEN-INDUCED OR ESTROGEN-STIMULATED | SRI INTERNATIONAL | 2002-09-24 | — | — | US | disclosed |
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2002-03-14 | — | — | US | disclosed |
| US-20020032181-A1 | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2002-03-14 | — | — | US | disclosed |
| US-6281205-B1 | 1,3,5(10)-ESTRATRIENE NUCLEUS, SUBSTITUTED AT THE C-17 POSITION WITH AN AMINE AND ETHER-CONTAINING GROUP | SRI INTERNATIONAL | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032181-A1 | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | HSD11B1 24/4885STS 597/4885HRH3 2058/4885 |
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | HSD11B1 22/4885STS 559/4885HRH3 2248/4885 |
| US-20020032180-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | HSD11B1 22/4885STS 559/4885HRH3 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.